Agarase YM01-3 mutant and application thereof

Through genetic engineering technology, the GH16 family agarase YM01-3 is mutation, which improves its thermal stability, solves the problem of poor thermal stability of agarase, and reduces the production cost of agarose oligosaccharides and improves the purity of the product, and promotes the promotion of Industrial production of agar oligosaccharides.

CN119040305AActive Publication Date: 2024-11-29XINXIANG MEDICAL UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411157071.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-22
Publication Date
2024-11-29
Estimated Expiration
2044-08-22

AI Technical Summary

Technical Problem

The poor thermal stability of the GH16 family agarase affects the agarose degradation efficiency, resulting in high production cost of agarose oligosaccharides and difficult to control the purity of the product.

Method used

GH16 family agarase YM01-3 was truncated by genetic engineering technology to construct agarase YM01-3 mutant to improve its thermal stability, and use pET-28a(+) vector in E.coli BL21 Expressed in (DE3), achieving efficient production of agarase.

Benefits of technology

It significantly improves the thermal stability of agarase, reduces the production cost of agar oligosaccharides, improves the purity and activity of the products, and promotes the industrial production of agar oligosaccharides.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119040305A_ABST
    Figure CN119040305A_ABST
Patent Text Reader

Abstract

According to the invention, the agarase YM01-3 is subjected to truncation mutation by utilizing a gene engineering technology, amplification is carried out by designing a pair of complementary sequence primers with opposite directions and applying high-fidelity DNA polymerase, only a part of genes in the DNA polymerase are amplified to construct a truncated recombinant DNA molecule, and the agarase YM01-3 mutant is finally constructed. The thermal stability of the agarase YM01-3 mutant is greatly improved compared with that of wild type YM01-3, and the agarase YM01-3 mutant is a novel agarase with great potential and can be applied to enzymatic industrial production of agaro-oligosaccharides, so that the production cost of the agaro-oligosaccharides is greatly reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of microbial enzymes, and particularly relates to an agarase YM01-3 mutant and an application thereof. Background Art

[0002] Agar, also known as agar, is the main component of carbohydrates in red algae cells, and its content reaches 60% of the dry weight of red algae. Agar can be converted into agar oligosaccharides after degradation. Agar oligosaccharides, also known as agar oligosaccharides, are oligosaccharides with a molecular weight between 300 and 2000. This oligosaccharide has a unique structure and properties, and is mainly composed of two repeating units: agarbiose and neoagarbiose. Agar oligosaccharides obtained by degrading agar not only retain some of the biological activities of agar, but also have better solubility and bioavailability due to its low molecular weight. In the health care product industry, agar oligosaccharides have attracted much attention for their whitening effects. Its unique molecular structure can closely bind to skin cells, promote cell metabolism, and thus improve skin color, making the skin whiter and more translucent. In addition, agar oligosaccharides also show excellent antioxidant capacity, which helps to resist the invasion of free radicals, delay cell aging, and protect physical health. In the field of medicine, the low calorie properties of agar oligosaccharides make it an ideal auxiliary treatment method. For diabetic patients, agar oligosaccharides not only have anti-diabetic potential, but also can reduce the calorie intake of patients while meeting their taste needs, which helps to control blood sugar levels. In addition, agar oligosaccharides also show antibacterial activity, which has a positive effect on preventing infection and promoting wound healing. In the cosmetics industry, the solubility and bioavailability of agar oligosaccharides make it a precious raw material. It can be easily integrated into various skin care products and cosmetics to exert its whitening, antioxidant and other effects and improve the overall quality of the product. In summary, agar oligosaccharides obtained by degrading agar have broad application potential in the health care products, pharmaceuticals and cosmetics industries.

[0003] Agar is mainly degraded into agar oligosaccharides by chemical and enzymatic methods. The chemical method is divided into acid degradation and redox method. The chemical method has high production cost, difficult product separation, and it is difficult to obtain high-purity products. The enzymatic method is more gentle and environmentally friendly, the production process is simple, the product is purified, and the oligosaccharide polymerization degree is uniform, so the activity is stable. The enzymatic method is more gentle and environmentally friendly. The use of enzymatic methods in the industrial production of oligosaccharides can improve production efficiency, simplify the production process, increase product activity and recovery rate, etc. Agarase, as an enzyme that can catalyze the degradation of agarose, belongs to five different glycoside hydrolase families, namely GH16, GH50, GH86, GH117 and GH118, and according to the type of glycosidic bond it cleaves agarose, agarase plays a key role in the green biodegradation of agarose.

[0004] At present, agarase of the GH16 family is one of the most widely studied enzymes. This family has many members, but their thermal stability shows significant differences. In the GH16 family, the optimum temperature of most agarases is around 40-50°C. On the other hand, studies have shown that the catalytic efficiency of agarase in liquid agarose solution is significantly better than that in the gel state, which may be related to the freer movement of molecules in the liquid and the smaller specific surface area of ​​the gel state. However, agarose solution can only present a fluid state at high temperature (≥50°C), which makes the thermal stability of agarase a key factor affecting the degradation efficiency of agarose. Exploring and modifying high-temperature resistant agarases has become the key to the high value-added utilization of agar and obtaining agar oligosaccharides with high purity and a specific degree of polymerization. It is a core issue that needs to be solved urgently. Summary of the invention

[0005] In view of the deficiencies in the prior art, the object of the present invention is to provide an agarase YM01-3 mutant with good thermal stability and its application.

[0006] In a first aspect of the present invention, a mutant of agarase YM01-3 is provided, which has higher thermal stability than the wild type.

[0007] In another preferred embodiment, the amino acid sequence of the agarase mutant has more than 95% homology with the amino acid sequence shown in SEQ ID NO.3, preferably 96% homology, more preferably 97%, 98%, 99% or 100% homology, and has higher thermal stability than the wild type.

[0008] In another preferred embodiment, the amino acid sequence of the agarase mutant is shown in SEQ ID NO.3.

[0009] In the second aspect of the present invention, a biological material related to the mutant of agarase according to the first aspect of the present invention is provided, wherein the biological material comprises at least one of the following 1)-5):

[0010] 1) A gene encoding the mutant of agarase according to the first aspect of the present invention;

[0011] 2) an expression cassette containing the coding gene described in 1);

[0012] 3) a recombinant vector containing the coding gene described in 1);

[0013] 4) A recombinant microorganism containing the coding gene described in 1);

[0014] 5) A recombinant microorganism containing the recombinant vector described in 3).

[0015] Further preferably, in 1), the nucleotide sequence of the encoding gene is a nucleotide sequence having more than 95% homology with the nucleotide sequence shown in SEQ ID NO.4, preferably 96% homology, more preferably 97%, 98%, 99% or 100% homology.

[0016] Further preferably, in 1), the nucleotide sequence of the encoding gene is as shown in SEQ ID NO.4.

[0017] More preferably, in 3), the recombinant vector uses pET-28a(+) vector as an expression vector.

[0018] More preferably, in 4) or 5), the recombinant microorganism is recombinant Escherichia coli BL21 (DE3).

[0019] In the third aspect of the present invention, there is provided use of the mutant of agarase according to the first aspect of the present invention in the decomposition of agar or agarose and the production of agar-oligosaccharide.

[0020] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here.

[0021] Compared with the prior art, the present invention has the following advantages and progress:

[0022] In the previous study, agarase YM01-3 (GenBank sequence number: AGU13985) of the GH16 family was isolated from Catenovulum agarivorans YM01. The present invention uses genetic engineering technology to perform truncation mutation on the agarase YM01-3, designs a pair of complementary sequence primers in opposite directions, uses a high-fidelity DNA polymerase for amplification, amplifies only a part of the gene, constructs a truncated recombinant DNA molecule, and finally constructs an agarase YM01-3 mutant. The thermal stability of the agarase YM01-3 mutant of the present invention is greatly improved compared with the wild-type AgaCA233. It is a new type of agarase with great potential, which can be applied to the enzymatic industrial production of agar oligosaccharides, thereby promoting a substantial reduction in the production cost of agar oligosaccharides. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] The accompanying drawings, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0024] Figure 1:PCR and double restriction enzyme digestion agarose gel electrophoresis. Lane 1: PCR amplified fragment; Lane 2: Recombinant plasmid pET-28a(+)-ym01-3m double restriction enzyme digestion verification; Lane M: marker.

[0025] Figure 2 : PCR verification of positive transformation colonies.

[0026] Figure 3 :SDS-PAGE electrophoresis detection of YM01-3 and YM01-3 mutants. (a) M: marker; lane 1: YM01-3 crude enzyme; lane 2: YM01-3 enzyme; lane 3: E. coli pET-28a(+) bacterial suspension protein; (b) M: marker; lane 1: YM01-3 mutant crude enzyme; lane 2: YM01-3 mutant pure enzyme; lane 3: E. coli pET-28a(+) bacterial suspension protein.

[0027] Figure 4 : Comparison of thermal stability of YM01-3 and YM01-3 mutant at 60℃.

[0028] Figure 5 : Galactose standard curve. DETAILED DESCRIPTION

[0029] The present invention provides a kind of agarase YM01-3 mutant and application. The present invention is specifically described below in conjunction with the embodiments to facilitate further understanding of the present invention by those skilled in the art. However, the embodiments described below are only part of the embodiments of the present invention and should not be regarded as any form of limitation of the present invention. It should be pointed out that the adjustments and improvements made by ordinary technicians in this field based on the concept of the present invention should be regarded as the protection scope of the present invention. The specific technical operation steps and operators are not indicated in the embodiments, and they are all carried out according to the general technical conditions described in the literature of the field or the relevant product instructions.

[0030] Example 1 Construction of recombinant expression plasmid of agarase YM01-3

[0031] In the previous study, agarase YM01-3 (GenBank sequence number: AGU13985) of the GH16 family was isolated from Catenovulum agarivorans YM01. According to the gene sequence of agarase ym01-3, NcoI and XhoI restriction sites were added at both ends, and then synthesized by a gene company according to the method of chemical total synthesis. Then, it was connected with the pET-28a(+) expression vector linearized by double restriction enzymes to construct the recombinant expression plasmid pET-28a(+)-ym01-3 of agarase YM01-3, which was transferred into Escherichia coli Top10 for amplification. After the plasmid was extracted, it was verified to be completely correct by sequencing.

[0032] Wild-type agarase YM01-3 amino acid sequence:

[0033] MYAADWDGVPIPAPAGQNKTWQIQSVSDDFNYTASANNKPNAFTSRWNDSYINAWLGPGDTEFSAGHSYTNSGKLALQAAEKTGTDKVYAGIISSKQTFTYPLYIE ARAKSTNNTMANAVWMLSADSTQELDAMEAYGSDRPGQEWFDRRMHVSHHVFIREPFQDYQPKDEGSWIYNEQEPWRVSYHNYGMHWKDPWNVDYYIDGVLVRSVS GPQMIDPNNFTNGTGINKPLHIIIDMEHQDWRDVKPTSAELADPAKSIFYVDWIRVYKPVDSGASAPTPPTGATSLQARHSSKCLDLSAGNSADGTNMQQWGCSAT NTNQDITFVAKGDGYYEMKTKHNKCIDVAGKETTNGANLVQWSCYNGTNPQFKLLDKGNGWFQLQAKHSGKCLEVVNSATTNGANVQQWACGNGNNQQWKFQ(SEQ ID NO.1).

[0034] Wild-type agarase ym01-3 gene DNA sequence:

[0035]

[0036] Using pET-28a(+)-ym01-3 as a template, primers F(-cbm) and R(-cbm) were used to perform PCR amplification of the mutant gene ym01-3m according to the following reaction system and reaction conditions.

[0037] Primer sequences for amplifying the agarase AgaCA233 mutant gene ym01-3m:

[0038] F(-cbm):TTTAAGAAGGAGATATACCATGGGC;

[0039] R(-cbm):

[0040] TGGTGGTGGTGGTGGTGCTCGAGTTTGTAGACCCTGATCCAATCTAC.

[0041] Table 1. PCR reaction system

[0042]

[0043] Table 2. PCR reaction process

[0044]

[0045] The target gene ym01-3m fragment amplified by the above PCR was connected to the plasmid pET-28a(+) linearized by double restriction enzyme digestion (NcoI and XhoI), and the target gene and the linearized vector were connected according to the connection system in Table 3 to obtain the YM01-3 mutant recombinant expression plasmid pET-28a(+)-ym01-3m.

[0046] Agarase YM01-3 mutant amino acid sequence:

[0047] MYAADWDGVPIPAPAGQNKTWQIQSVSDDFNYTASANNKPNAFTSRWNDSYINAWLGPGDTEFSAGHSYTNSGKLALQAAEKTGTDKVYAGIISSKQTFTYPLYIEARAKSTNNTMANAVWMLSADSTQELDAMEAY GSDRPGQEWFDRRMHVSHHVFIREPFQDYQPKDEGSWIYNEQEPWRVSYHNYGMHWKDPWNVDYYIDGVLVRSVSGPQMIDPNNFTNGTGINKPLHIIIDMEHQDWRDVKPTSAELADPAKSIFYVDWIRVYK(SEQ ID NO.3).

[0048] DNA sequence of the agarase ym01-3m mutant gene:

[0049] ATGTATGCAGCAGACTGGGATGGTGTACCGATTCCGGCACCAGCAGGTCAAAACAAAACTTGGCAAATACAATCTGTGTCAGATGATTTTAACTACACAGCTTCAGCCAATAATAAACCAAACGCTTTTACCAGTCGTTGGAACGACAGCTATATTAATGCGTGGTTAGGGCCTGGTGATACTGAATTTAGTGCAGGTCATTCGTACACAAATTCAGGCAAACTGGCTTTGCAAGCTGCTGAAAAAACAGGTACAGACAAAGTATACGCAGGTATTATTTCTTCAAAACAAACATTTACCTATCCGCTTTATATTGAAGCGCGGGCAAAATCAACCAACAACACTATGGCGAATGCAGTATGGATGTTAAGTGCTGATTCAACTCAAGAATTAGATGCAATGGAAGCTTATGGTAGTGATAGGCCAGGCCAAGAATGGTTTGATCGTCGTATGCATGTGAGCCATCATGTATTTATTCGCGAACCATTCCAAGATTATCAACCAAAAGACGAAGGCTCTTGGATATACAATGAGCAAGAGCCATGGCGCGTTTCTTATCACAACTATGGTATGCATTGGAAAGATCCTTGGAATGTTGATTATTACATTGATGGTGTTTTAGTTAGAAGTGTCTCTGGCCCTCAAATGATTGATCCAAATAACTTCACCAACGGCACAGGTATCAACAAACCATTACATATTATTATTGATATGGAACATCAAGACTGGCGCGATGTTAAACCAACGTCTGCTGAGCTTGCAGATCCTGCAAAAAGTATTTTTTATGTAGATTGGATCAGGGTCTACAAA(SEQ ID NO.4).

[0050] Table 3. Ligation system of the target gene and the vector

[0051]

[0052] The amplified product was detected by 1% agarose gel electrophoresis ( Figure 1 ), showing that the size of the PCR product is consistent with the size of the YM01-3 mutant, and the YM01-3 plasmid was double-digested ( Figure 1 ) and gel recovery, the gel recovery product is consistent with the target gene fragment size. The PCR fragment and the restriction plasmid were connected and screened on LB medium containing kanamycin to obtain positive colonies. Agarose gel electrophoresis ( Figure 2 ), containing the target band, and the positive colonies were sent to Sangon Biotech (Shanghai) Co., Ltd. for sequencing. The sequencing results were completely consistent with the mutant design gene sequence, confirming that the mutant enzyme genetic engineering strain was successfully constructed.

[0053] Example 3 Inducible expression of agarase YM01-3 and YM01-3 mutants in Escherichia coli

[0054] The plasmids pET-28a(+)-ym01-3 and pET-28a(+)-ym01-3m were transformed into competent cells of Escherichia coli BL21(DE3) according to the following method to obtain YM01-3 and YM01-3 mutant engineered strains E. coli BL21(DE3) / pET-28a(+)-ym01-3 and E. coli BL21(DE3) / pET-28a(+)-ym01-3m.

[0055] (1) Take 5 μL of recombinant plasmid sample and add it to 50-100 μL of competent cells, mix slowly and place on ice for 30 min.

[0056] (2) Heat shock for 90 seconds (42°C water bath), then quickly return to the ice bath and wait for 3 to 5 minutes.

[0057] (3) Add 500 μL LB liquid culture medium (without antibiotics), mix gently, and culture with shaking for 1 h (37°C).

[0058] (4) Centrifuge the bacterial solution (5000 rpm, 1 min) to precipitate the bacteria and aspirate most of the supernatant (about 50-100 μL of the remaining resuspended bacteria).

[0059] (5) Spread the bacterial solution evenly on LB plates (containing Kana antibiotics) and culture in a 37°C incubator overnight.

[0060] (6) Pick a single colony on the LB plate and culture it. Take 50 μL of the bacterial solution and send it for testing to determine whether the recombinant strain is correct.

[0061] The successfully constructed genetically engineered strains E.coli BL21(DE3) / pET-28a(+)-ym01-3 and E.coliBL21(DE3) / pET-28a(+)-ym01-3m were inoculated into 5mL LB medium and cultured on a shaker for 12h (37°C, 220rpm) as seed solution. 200μL of seed solution was inoculated into 200mL LB medium (containing Kana), and after shaking culture for 2h (37°C, 220rpm), 200μL IPTG (0.5M) was added at a ratio of 1‰, and shaken culture was performed for 20-24h (16°C, 220rpm) to induce the expression of the target protein. The cells were collected and the supernatant was discarded after centrifugation. Add 15mL of lysis buffer (Tris 20mM, NaCl20mM, DTT 1mM, imidazole 20mM, pH 7.0) to the bacteria, and place it on an ice-water mixture for ultrasonic disruption (power 260-300W, total disruption time 30min, working time 3s, interval time 3s). After the ultrasound is completed, centrifuge again (4℃, 8000rpm) for 40min, and the resulting supernatant is the crude enzyme solution. The crude enzyme solution was purified using a nickel column His Trap TM HP-5mL. Add 5×SDS loading buffer to the enzyme solution, mix well, boil for 10min, then centrifuge at 12000rpm for 10min, and perform SDS-PAGE protein electrophoresis on the supernatant with 5% concentrated gel and 12% separation gel. Results ( Figure 3 ) showed that YM01-3 and YM01-3 mutants were successfully expressed, with sizes consistent with expectations, about 50 kD and 30 kD, respectively, and the degree of purification was close to the electrophoretic purity.

[0062] Example 4 Comparison of thermal stability of agarase YM01-3 and YM01-3 mutant and determination of agar degradation ability of YM01-3 mutant

[0063] Method for determining enzyme activity: dilute agarase to an appropriate concentration, add the following reaction system (Table 4) to a 1.5 mL EP tube, react in a 60°C water bath for 20 min, add 300 μL DNS solution after the reaction, and boil in a boiling water bath for 7 min (do three sets of experiments in parallel), take 200 μL in a 96-well plate, and use a microplate reader to measure the OD value at 540 nm.

[0064] Table 4 Agarase reaction system

[0065]

[0066] At 60°C, the YM01-3 mutant still had about 60% enzyme activity after being incubated for 2.5 h, while the residual enzyme activity of YM01-3 was only about 33% ( Figure 4). The thermal stability of YM01-3 mutants is better than that of YM01-3.

[0067] Agarase YM01-3 mutant degrades agarose to produce oligosaccharides. The DNS reducing sugar test method is used to determine the generation of the reaction product, and the reducing sugar galactose is used as the standard to calculate the amount of the product. Prepare different concentrations of galactose solution, take 300μL in a 1.5mL EP tube, and add 300μL DNS to the tube. After boiling in a water bath for 7 minutes, measure the OD values ​​of different concentrations of galactose, and draw a standard curve based on the concentration and OD value ( Figure 5 ) was used as a standard curve for the quantification of oligosaccharides generated by agarase degradation of agarose.

[0068] It is proposed to stipulate that the amount of enzyme required to hydrolyze agarose to produce 1 μg of reducing sugar (galactose) per unit time (per minute) is 1 enzyme activity unit (U). Specific enzyme activity = total activity (U) / [enzyme protein concentration (mg / mL) × enzyme solution volume].

[0069] The enzyme activity of agarase YM01-3 mutant was measured at 65°C, and the specific enzyme activity of agarase YM01-3 mutant was determined based on its enzyme concentration. The results showed that the specific enzyme activity of YM01-3 mutant was 832U / mg, indicating that agarase YM01-3 mutant has a higher ability to degrade agar.

[0070] The above is only a preferred embodiment of the present invention and does not limit the present invention in any way. For those skilled in the art, any modification and change made to the above embodiment according to the technical essence of the present invention shall fall within the protection scope of the technical solution of the present invention.

Claims

1. A mutant of agarase YM01-3, characterized in that: The amino acid sequence of the mutant has more than 95% homology with the amino acid sequence shown in SEQ ID NO.3, preferably 96% homology, more preferably 97%, 98%, 99% or 100% homology, and has higher thermal stability than the wild type.

2. The mutant of agarase YM01-3 according to claim 1, characterized in that The amino acid sequence of the mutant is shown in SEQ ID NO.

3.

3. A biological material related to the mutant of agarase YM01-3 according to claim 1 or 2, wherein the biological material comprises at least one of the following 1)-5): 1) A gene encoding a mutant of agarase YM01-3 according to claim 1 or 2; 2) an expression cassette containing the coding gene described in 1); 3) a recombinant vector containing the coding gene described in 1); 4) A recombinant microorganism containing the coding gene described in 1); 5) A recombinant microorganism containing the recombinant vector described in 3).

4. The biomaterial according to claim 3, characterized in that The nucleotide sequence encoding the gene in 1) is a nucleotide sequence having more than 95% homology with the nucleotide sequence shown in SEQ ID NO.4, preferably 96% homology, more preferably 97%, 98%, 99% or 100% homology.

5. The biomaterial according to claim 3, characterized in that The nucleotide sequence of the gene encoded in 1) is shown in SEQ ID NO.

4.

6. Use of the mutant of agarase YM01-3 according to claim 1 or 2 in agar decomposition and agar oligosaccharide production.

Citation Information

Patent Citations

  • Beta-agarase and recombinant expression strain

    CN103194420A

  • Modified agarase and application thereof

    CN109576247A

  • Agarase mutant with improved thermal stability and application thereof

    CN114836405A

  • Agarase Mutant with Improved Thermal Stability and Application Thereof

    US20240060062A1